Caribou Biosciences, Inc. (CRBU)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 65/100 (HIGH), 2.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 13.63% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- In the hunt for reverse merger targets, Caribou could be prized game
- Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate
- CRBU Stock Crashes 35% Premarket — RBC Slashes Target By 90% After Caribou Scraps CAR-T Programs
- Caribou Biosciences stock plunges 40% on halt of CAR-T programs
- Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
- Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
- BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.
- Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Caribou Biosciences, Inc..
Full CRBU Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.